ProfileGDS5678 / 1431898_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 32% 33% 33% 34% 34% 47% 48% 33% 33% 34% 33% 34% 33% 33% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7637732
GSM967853U87-EV human glioblastoma xenograft - Control 22.7490633
GSM967854U87-EV human glioblastoma xenograft - Control 32.7583633
GSM967855U87-EV human glioblastoma xenograft - Control 42.7183934
GSM967856U87-EV human glioblastoma xenograft - Control 52.7207334
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1975247
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.2190348
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.736333
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7334133
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7480434
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7384633
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7389134
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7502633
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7457433